<DOC>
	<DOCNO>NCT01554059</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination cytotoxic chemotherapy ( Oxaliplatin 5Fu ) bevacizumab concomitantly radiotherapy neoadjuvant treatment patient locally advance resectable rectal adenocarcinoma .</brief_summary>
	<brief_title>Neoadjuvant Chemoradiation With Bevacizumab Chinese Rectal Cancer Patients</brief_title>
	<detailed_description>Primary endpoint : Pathological Complete Response Rate ( pCR ) Secondary endpoint : Time Relapse , disease free survival , overall survival safety data</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>ECOG status 0 1 . All patient must histologically confirm adenocarcinoma rectum . The clinical stage must T3 , T4 , regional lymphnode involvement base CT , MRI EUS criterion . Criteria pathologic enlargement lymph node &gt; 15 mm short axis dimension . If CT finding lung , liver , peritoneal metastasis equivocal , patient eligible participate . All patient must distant metastatic disease abdominopelvic CT scan perform IV contrast . The rectal tumor must either palpable digital rectal exam inferior edge tumor must within 12 cm anal verge base rigid proctoscopy . Patients must WBC &gt; 4*10E9/L , ANC &gt; 1.5 *10E9/L , platelet &gt; 100*10E9/L , Hemoglobin &gt; 90 g/L adequate hepatic renal function . Patients must sign informed consent indicate aware investigational nature study , aware participation voluntary . Known compromised renal hepatic function . Participation experimental drug study . AST ALT &gt; 5 time upper limit normal subject document liver metastasis ; &gt; 2.5 time upper limit normal subject without evidence liver metastasis . Pregnant lactate woman . Woman childbearing potential either positive pregnancy test baseline . Woman/men childbearing potential use reliable contraceptive method . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patients must agree continue contraception 30 day date last study drug administration . Any prior chemotherapy . Any prior radiation therapy . Serious , uncontrolled , concurrent infection ( ) require IV antibiotic . Treatment carcinoma within last five year , except cure nonmelanoma skin cancer treat insitu cervical cancer . Clinically significant cardiac disease ( e.g. , uncontrolled hypertension [ blood pressure &gt; 160/110 mmHg medication ] , history myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix H ) , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia eligible ) , grade II great peripheral vascular disease ( see Appendix H ) . Evidence bleed diathesis coagulopathy , INR great equal 1.5 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study ; fine needle aspiration core biopsy within 7 day prior Day 0 . Proteinuria baseline clinically significant impairment renal function Subjects unexpectedly discover 1+ proteinuria baseline undergo 24hour urine collection , must adequate collection must demonstrate &lt; 500 mg protein/24 hr allow participation study . Currently serious , nonhealing wound , ulcer , bone fracture . Had aneurysm , stroke , transient ischemic attack , arteriovenous malformation within past year . Patients organ allograft . Patients take cimetidine must drug discontinue . Ranitidine drug another antiulcer class substitute cimetidine necessary . If patient currently receive allopurinol , must discuss PI see another agent may substitute .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Rectal cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Chemoradiation</keyword>
</DOC>